In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes

Drug Metabolism and Disposition

Volumn 35, Issue 12, 2007, Pages 2252-2261

  Aprile, Silvio ^a   Del Grosso, Erika ^a   Tron, Gian Cesare ^a   Grosa, Giorgio ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4; QUINONE DERIVATIVE; STILBENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; ELECTROSPRAY MASS SPECTROMETRY; EPOXIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOMERIZATION; LIVER MICROSOME; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; TANDEM MASS SPECTROMETRY;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEALKYLATION; HUMANS; HYDROXYLATION; ISOMERISM; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; QUINONES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; STILBENES; TANDEM MASS SPECTROMETRY; TUBULIN MODULATORS;

RATTUS;

EID: 36349000649     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016998     Document Type: Article

References (25)

1. Bolton JL, Trush MA, Penning TM, Dryhurst G, and Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135-160.
2. Cardona ML, Fernandez MI, Garcia MB, and Pedro JR (1986) Synthesis of natural polyhydroxystilbenes. Tetrahedron 42:2725-2730.
3. Daly J, Horner L, and Witkop B (1961) Chemical and enzymatic routes to methoxydopamines. J Am Chem Soc 83:4787-4791.
4. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, and Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834.
5. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, et al. (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416.
6. Gaukroger K, Hadfield JA, Hepworth LA, Lawrence NJ, and McGown AT (2001) Novel syntheses of cis and trans isomers of combretastatin A-4. J. Org Chem 66:8135-8138.
7. Grosa G, Galli U, Rolando B, Fruttero R, Gervasio G, and Gasco A (2004) Identification of 2,3-diaminophenazine and of o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan. Xenobiotica 34:345-352.
8. Grosios K, Holwell SE, McGown AT, Pettit GR, and Bibby MC (1999) In vivo and in vitro evaluation of combretastatin-A4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327.
9. Kaisalo L, Latvala A, and Hase T (1986) Selective demethylations in 2,3,4-trimethoxyaryl carbonyl compounds. Synth Commun 16:645-648.
10. Kirwan IG, Loadman PM, Swaine DJ, Antoney DA, Pettit GR, Lippert JW III, Shnyder SD, Cooper PA, and Bibby MC (2004) Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 10:1446-1453.
11. Kong Y, Grembecka J, Edler MC, Hamel E, Mooberry SL, Sabat M, Rieger J, and Brown ML (2005) Structure-based discovery of boronic acid bioisostere of combretastatin A-4. Chem Biol 12:1007-1014.
12. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, and Hamel E (1988) Interactions of tubulin with potent natural and synthetic analogs of antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34:200-208.
13. Lippert JW (2007) Vascular disrupting agents. Bioorg Med Chem 15:605-615.
14. Mealy NE, Lupone B, and Balcell M (2006) Drugs under development for the treatment of breast cancer: combretastatin A-4 phosphate. Drug Fut 31:547-548.
15. McGown AT and Fox BV (1989) Structural and biochemical comparison of the antimitotic agents colchicine, combretastatin-A4 and amphetinile. Anticancer Drug Des 3:249-254.
16. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:3137-3142.
17. Pettit GR, Singh SB, Niven ML, Hamel E, and Schmidt JM (1987) Antineoplastic agent 124. Isolation, structure and synthesis of combretastatin-A1 and combretastatin-B1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50:119-131.
18. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, and Garciakendall D (1989) Antineoplastic agent 145. Isolation and structure of the strong cell-growth and tubulin inhibitor combretastatin-A4. Experientia 45:209-211.
19. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, and Boyd MR (1995) Antineoplastic agents 322. Synthesis of combretastatin-4 prodrugs. Anticancer Drug Des 10:299-309.
20. Rustin GJS, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, and Price PM (2003) Phase I clinical trial of weakly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2282.
21. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, et al. (2003) Phase I trial of the antivascular agent combretastatin A-4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438.
22. Stratford MRL and Dennis ML (1999) Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography. J Chromatogr B 721:77-85.
23. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL, Dennis MF, and Chaplin DJ (1999) Combretastatin-A4 phosphate as a tumor-vascular targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634.
24. Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, and Genazzani AA (2006) Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 49:3033-3044.
25. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG, and van Breemen RB (2002) Human, rat, and mouse metabolism of resveratrol. Pharmacol Res 19:1907-1914.